Cargando…
Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts dire...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140324/ https://www.ncbi.nlm.nih.gov/pubmed/35645815 http://dx.doi.org/10.3389/fphar.2022.856747 |
_version_ | 1784715068214083584 |
---|---|
author | De Marco, Corrado Charron, Thierry Rousseau, Guy |
author_facet | De Marco, Corrado Charron, Thierry Rousseau, Guy |
author_sort | De Marco, Corrado |
collection | PubMed |
description | The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts directly with the sequential pathophysiological processes culminating in reperfusion injury by inhibiting them upstream. The evidence for adenosine’s benefit in acute myocardial infarction has produced mixed results with regards to myocardial salvage and long-term mortality. The heterogenous evidence with regards to benefits on clinical outcomes has resulted in modest uptake of adenosine in the clinical setting. However, it is critical to analyze the variability in study methodologies. The goal of this review is to evaluate how adenosine dose, route of administration, timing of administration, and site of administration play essential roles in the molecule’s efficacy. The benefits of adenosine, as highlighted in the following review, are clear and its role in the treatment of acute myocardial infarction should not be discounted |
format | Online Article Text |
id | pubmed-9140324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91403242022-05-28 Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? De Marco, Corrado Charron, Thierry Rousseau, Guy Front Pharmacol Pharmacology The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts directly with the sequential pathophysiological processes culminating in reperfusion injury by inhibiting them upstream. The evidence for adenosine’s benefit in acute myocardial infarction has produced mixed results with regards to myocardial salvage and long-term mortality. The heterogenous evidence with regards to benefits on clinical outcomes has resulted in modest uptake of adenosine in the clinical setting. However, it is critical to analyze the variability in study methodologies. The goal of this review is to evaluate how adenosine dose, route of administration, timing of administration, and site of administration play essential roles in the molecule’s efficacy. The benefits of adenosine, as highlighted in the following review, are clear and its role in the treatment of acute myocardial infarction should not be discounted Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9140324/ /pubmed/35645815 http://dx.doi.org/10.3389/fphar.2022.856747 Text en Copyright © 2022 De Marco, Charron and Rousseau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology De Marco, Corrado Charron, Thierry Rousseau, Guy Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title | Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title_full | Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title_fullStr | Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title_full_unstemmed | Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title_short | Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? |
title_sort | adenosine in acute myocardial infarction-associated reperfusion injury: does it still have a role? |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140324/ https://www.ncbi.nlm.nih.gov/pubmed/35645815 http://dx.doi.org/10.3389/fphar.2022.856747 |
work_keys_str_mv | AT demarcocorrado adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole AT charronthierry adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole AT rousseauguy adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole |